Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Shareholder Meeting (March 2024)
28 slides from Zealand Pharma A/s's shareholder meeting presentation, Mar 20, 2024
Slide 1: Annual General Meeting 2024
Annual General Meeting 2024 Zealand Pharma March 20, 2024
Slide 2: Introduction and report from the Chairman
Introduction and report from the Chairman. Martin Nicklasson Chairman of the Board 2
Slide 3: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 4: Agenda
Agenda 1. Management’s report on the Company's activities during the past financial year 2. Approval of the audited Annual Report 2023 3. Resolution on the cover of loss in accordance with the approved Annual Report 2023 4. Election of members to the Board of Directors 5. Election of the auditor 6.
Slide 5: Agenda: Management's report
Agenda: Management’s report 1. Management’s report on the Company's activities during the past financial year a) Martin Nicklasson (Chairman): Introduction and report from the Chairman b) Adam Steensberg (CEO): Management report for 2023 c) Henriette Wennicke (CFO): Financial highlights 2023 d) Thom
Slide 6: Management report for 2023
Management report for 2023 Adam Steensberg President & Chief Executive Officer 6
Slide 7: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Dapiglutide (GLP-1R/GLP-2R dual agonist) Obesity Obesity Petrelintide (amylin analog) Obesity ZP6590 (GIP receptor agonist) Obesity Survodu
Slide 8: In 2024 we are expanding efforts to advance our pipeline of differentiated obesity assets
In 2024 we are expanding efforts to advance our pipeline of differentiated obesity assets Petrelintide Dapiglutide Survodutide2 (amylin analog) (GLP-1R/GLP-2R) (GCGR/GLP-1R) Phase 1b 16-week MAD clinical Phase 2a DREAM clinical trial trial data data1 Phase 2 MASH clinical trial data Phase 2b trial i
Slide 9: Financial highlights 2023
Financial highlights 2023 Henriette Wennicke Chief Financial Officer
Slide 10: 2023 FY Profit & Loss
2023 FY Profit & Loss DKK million 2023 FY 2022 FY P&L reflecting Zealand’s investment in its differentiated assets targeting obesity Revenue 342.8 104.0 • Revenue of DKK 343 million is driven by milestones from Boehringer Ingelheim for Gross profit 323.6 104.0 survodutide and Sanofi for lixisenatide
Slide 11: Solid cash position allows for investments in R&D
Solid cash position allows for investments in R&D DKK 4.1 billion cash position including January 2024 capital raise, RCF and EIB loan facilities1 4,104 DKK million 1,450 671 1,633 350 1,178 1,500 -1,045 Cash position Change in cash2 Apr-23 Cash position Revolving European Jan-24 Cash position Dec-2
Slide 12: 2024 financial guidance
2024 financial guidance DKK million 2024 2023 Guidance Actual Revenue anticipated from existing and new license and No guidance 343 partnership agreements due to uncertain size and timing Net operating expenses1 1,100 – 1,200 896 Notes 1. Net operating expenses consist of R&D, S&M, G&A and other ope
Slide 13: Comments & Questions
Comments & Questions y
Slide 14: Agenda items 1, 2, 3 – Joint Resolutions
Agenda items 1, 2, 3 – Joint Resolutions 1. Management’s report on the Company's activities during the past financial year 2. Approval of the audited Annual Report 2023 3. Resolution on the cover of loss in accordance with the approved Annual Report 2023 14
Slide 15: Agenda item 4 (1/2): Election of members to the Board
Agenda item 4 (1/2) Election of members to the Board of Directors The following board members are standing for re-election and the Board of Directors proposes re-election of all the members in accordance with the recommendation from the Nomination Committee: Kirsten A. Drejer Jeffrey Berkowitz Leona
Slide 16: Agenda item 4 (2/2): Election of members to the Board
Agenda item 4 (2/2) Election of members to the Board of Directors Further, in accordance with the recommendation of the Nomination Committee, the Board of Directors proposes to elect as new members of the Board of Directors. Elaine Sullivan Enrique Conterno Special competencies: Special competencies
Slide 17: Comments & Questions
Comments & Questions y
Slide 18: Agenda item 5: Election of the auditor
Agenda item 5 Election of the auditor The Board of Directors proposes that PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab ("PwC") be elected as the Company's new auditor for both financial and sustainability reporting purposes in accordance with the Audit Committee's recommendation.
Slide 19: Agenda item 6: Authorization to acquire treasury shares
Agenda item 6 Authorization for the Company to acquire treasury shares directly The Board of Directors requests that the General Meeting authorizes the Company to acquire, during the period until the next Annual General Meeting, treasury shares directly, provided the acquisition, pursuant to Section
Slide 20: Agenda item 7: Amend the Remuneration Policy
Agenda item 7 Proposal from the Board of Directors to amend the Company's Remuneration Policy The Board of Directors proposes that the general meeting amend the Company's Remuneration policy with changes to the value caps for RSU to the Board of Directors as well as changes to the short- and long-te
Slide 21: Comments & Questions
Comments & Questions y
Slide 22: Agenda item 8: Approve the Remuneration Report
Agenda item 8 Proposal from the Board of Directors to approve the Company's Remuneration Report The Board of Directors proposes that the general meeting approves the Company's Remuneration Report for the financial year 2023. The vote on the Remuneration Report is a non-binding advisory vote. 22
Slide 23: Agenda item 9: Approve board fees for 2024
Agenda item 9 Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2024 The Board of Directors proposes that the General Meeting approves the fees for the Board of Directors for the financial year 2024 (not increased and therefore remain unchanged
Slide 24: Agenda item 10: Authorization to increase the share capital
Agenda item 10 Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of cash contribution without pre-emption rights for the Company's existing shareholders and at market price "Bestyrelsen er i perioden indtil den 20. "During the per
Slide 25: Agenda item 11: Renew and increase authorization to issue warrants
Agenda item 11 Proposal from the Board of Directors to renew and increase the existing authorization to issue warrants "Generalforsamlingen har den 20. marts "On 20 March 2024, the general meeting de- The Board of Directors proposes that the General 2024 besluttet at forhøje og forlænge cided to ext
Slide 26: Agenda item 12: Indemnification scheme for board and management
Agenda item 12 Proposal from the Board of Directors to approve the introduction of an indemnification scheme for the Board of Directors and Executive Management of the Company. The Company has taken out customary directors’ and officers’ liability insurance (“D&O Insurance”) for certain personal lia
Slide 27: Agenda item 13: Any other business
Agenda item 13 Any other business 27
Slide 28: Thank you
Thank you Zealand Pharma Annual General Meeting March 20, 2024